TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)
Brief Summary: The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.


Options:
A: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Other: Standard of care | Arm Label: Evolocumab + SOC; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + SOC, Standard of Care | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of Care
B: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Drug: Placebo (for Alirocumab) | Arm Label: Alirocumab 75/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for Ezetimibe) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for Ezetimibe); Assigned to Arm(s): Alirocumab 75/Up to 150 mg Q2W
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter Evaluation of Safety, Pharmacokinetics and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia B
Brief Summary: The primary objective of the study is to evaluate the safety of Recombinant Human Coagulation Factor IX Fc Fusion Protein (rFIXFc) in previously treated pediatric subjects with hemophilia B. Secondary objectives of this study in this study population are as follows: to evaluate the efficacy of rFIXFc for prevention and treatment of bleeding episodes; to evaluate and assess the pharmacokinetics (PK) of rFIXFc; to evaluate rFIXFc consumption for prevention and treatment of bleeding episodes


Options:
A: Arm Label: Pharmacokinetic (PK) evaluation of BAX 855; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Arm Label: FVIII trough target 1-3%; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Arm Label: FVIII trough target 8-12%; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Pharmacokinetic (PK) evaluation of BAX 855 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): FVIII trough target 1-3% | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): FVIII trough target 8-12%
B: Arm Label: BAY94-9027 and Elocta; Type: EXPERIMENTAL; Interventions: Drug: Damoctocog (Jivi, BAY94-9027), Drug: Elocta | Arm Label: Elocta and BAY94-9027; Type: EXPERIMENTAL; Interventions: Drug: Damoctocog (Jivi, BAY94-9027), Drug: Elocta | Intervention Type: DRUG; Name: Damoctocog (Jivi, BAY94-9027); Assigned to Arm(s): BAY94-9027 and Elocta, Elocta and BAY94-9027 | Intervention Type: DRUG; Name: Elocta; Assigned to Arm(s): BAY94-9027 and Elocta, Elocta and BAY94-9027
C: Arm Label: rFIXFc Prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: rFIXFc, Drug: FIX | Intervention Type: DRUG; Name: rFIXFc; Assigned to Arm(s): rFIXFc Prophylaxis | Intervention Type: DRUG; Name: FIX; Assigned to Arm(s): rFIXFc Prophylaxis
D: Arm Label: On-Demand; Type: EXPERIMENTAL; Interventions: Drug: rFVIIIFc | Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: rFVIIIFc | Intervention Type: DRUG; Name: rFVIIIFc; Assigned to Arm(s): On-Demand, Prophylaxis

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: With preterm birth, the ingestion of amniotic fluid containing enterocyte trophic factors ceases abruptly. This likely predisposes them to villous atrophy feeding intolerance and necrotizing enterocolitis(NEC) once feedings are instituted.Granulocyte Colony-Stimulating Factor (G-CSF) and Erythropoietin (EPO) have important non-hematopoietic roles in human developmental biology. Among these roles, they have trophic actions on villous height and bowel length of the developing intestine.The aim of this study is to evaluate the efficacy of enteral recombinant human G-CSF and recombinant human EPO in prevention of feeding intolerance and /or NEC in preterm infants.


Options:
A: Arm Label: Darbepoetin alfa injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa Injection | Arm Label: erythropoietin alfa injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: erythropoietin alfa injection | Arm Label: placebo/control; Type: PLACEBO_COMPARATOR; Interventions: Drug: sham injection | Intervention Type: DRUG; Name: Darbepoetin Alfa Injection; Assigned to Arm(s): Darbepoetin alfa injection | Intervention Type: DRUG; Name: erythropoietin alfa injection; Assigned to Arm(s): erythropoietin alfa injection | Intervention Type: DRUG; Name: sham injection; Assigned to Arm(s): placebo/control
B: Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Recombinant human Erythropoietin | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: Recombinant human Erythropoietin; Assigned to Arm(s): Erythropoietin | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline
C: Arm Label: Indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: G-CSF; Type: EXPERIMENTAL; Interventions: Drug: rh G-CSF | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: rh EPO | Arm Label: G-CSF and EPO; Type: EXPERIMENTAL; Interventions: Drug: recombinant human G-CSF, and rhEPO, Drug: rh G-GSF and rh EPO together | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: recombinant human G-CSF, and rhEPO; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: rh G-CSF; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: rh EPO; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: rh G-GSF and rh EPO together; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: With preterm birth, the ingestion of amniotic fluid containing enterocyte trophic factors ceases abruptly. This likely predisposes them to villous atrophy feeding intolerance and necrotizing enterocolitis(NEC) once feedings are instituted.Granulocyte Colony-Stimulating Factor (G-CSF) and Erythropoietin (EPO) have important non-hematopoietic roles in human developmental biology. Among these roles, they have trophic actions on villous height and bowel length of the developing intestine.The aim of this study is to evaluate the efficacy of enteral recombinant human G-CSF and recombinant human EPO in prevention of feeding intolerance and /or NEC in preterm infants.


Options:
A: Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Recombinant human Erythropoietin | Arm Label: saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: Recombinant human Erythropoietin; Assigned to Arm(s): Erythropoietin | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline
B: Arm Label: G-CSF; Type: EXPERIMENTAL; Interventions: Drug: rh G-CSF | Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: rh EPO | Arm Label: G-CSF and EPO; Type: EXPERIMENTAL; Interventions: Drug: recombinant human G-CSF, and rhEPO, Drug: rh G-GSF and rh EPO together | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: recombinant human G-CSF, and rhEPO; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: rh G-CSF; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: rh EPO; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: rh G-GSF and rh EPO together; Assigned to Arm(s): G-CSF and EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: preterm ESA recipients; Type: N/A; Interventions: N/A | Arm Label: preterm controls; Type: N/A; Interventions: N/A | Arm Label: term controls; Type: N/A; Interventions: N/A
D: Arm Label: Indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Prospective Multicenter Trial of Pancreas Resection With and Without Routine Intraperitoneal Drainage
Brief Summary: This randomized prospective trial is designed to test the hypothesis that pancreatectomy without routine intraperitoneal drainage does not increase the severity or frequency of complications within 60 days of surgery.


Options:
A: Arm Label: Early drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Arm Label: Standard drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Intervention Type: PROCEDURE; Name: Postoperative drain removal; Assigned to Arm(s): Early drain removal, Standard drain removal
B: Arm Label: One-layer duct-to-mucosa Group; Type: EXPERIMENTAL; Interventions: Procedure: Modified one-layer duct-to-mucosa Pancreaticojejunostomy | Arm Label: Invagination Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Invagination pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: Modified one-layer duct-to-mucosa Pancreaticojejunostomy; Assigned to Arm(s): One-layer duct-to-mucosa Group | Intervention Type: PROCEDURE; Name: Invagination pancreaticojejunostomy; Assigned to Arm(s): Invagination Group
C: Arm Label: Standard drainage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard drain removal | Arm Label: Short drainage; Type: EXPERIMENTAL; Interventions: Procedure: Drain removal at D4 | Intervention Type: PROCEDURE; Name: Drain removal at D4; Assigned to Arm(s): Short drainage | Intervention Type: PROCEDURE; Name: Standard drain removal; Assigned to Arm(s): Standard drainage
D: Arm Label: No Drains; Type: EXPERIMENTAL; Interventions: Procedure: No Drains | Arm Label: Drains; Type: EXPERIMENTAL; Interventions: Procedure: Drains | Intervention Type: PROCEDURE; Name: No Drains; Assigned to Arm(s): No Drains | Intervention Type: PROCEDURE; Name: Drains; Assigned to Arm(s): Drains

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Prospective Multicenter Trial of Pancreas Resection With and Without Routine Intraperitoneal Drainage
Brief Summary: This randomized prospective trial is designed to test the hypothesis that pancreatectomy without routine intraperitoneal drainage does not increase the severity or frequency of complications within 60 days of surgery.


Options:
A: Arm Label: No Drains; Type: EXPERIMENTAL; Interventions: Procedure: No Drains | Arm Label: Drains; Type: EXPERIMENTAL; Interventions: Procedure: Drains | Intervention Type: PROCEDURE; Name: No Drains; Assigned to Arm(s): No Drains | Intervention Type: PROCEDURE; Name: Drains; Assigned to Arm(s): Drains
B: Arm Label: Closed suction drain; Type: ACTIVE_COMPARATOR; Interventions: Procedure: closed suction drain | Arm Label: Closed gravity drain; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Closed gravity drain | Intervention Type: PROCEDURE; Name: Closed gravity drain; Assigned to Arm(s): Closed gravity drain | Intervention Type: PROCEDURE; Name: closed suction drain; Assigned to Arm(s): Closed suction drain
C: Arm Label: Early drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Arm Label: Standard drain removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Postoperative drain removal | Intervention Type: PROCEDURE; Name: Postoperative drain removal; Assigned to Arm(s): Early drain removal, Standard drain removal
D: Arm Label: SOM230; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide (SOM230) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Pasireotide (SOM230); Assigned to Arm(s): SOM230 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus
Brief Summary: Hypothesis: Chronic intake of pistachios improves glucose metabolism and insulin resistance status thus contributing to decrease the risk of type 2 diabetes mellitus and its associated abnormalities.


Options:
A: Arm Label: Brazil Nuts; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Brazil Nut | Intervention Type: DIETARY_SUPPLEMENT; Name: Brazil Nut; Assigned to Arm(s): Brazil Nuts
B: Arm Label: Control diet; Type: ACTIVE_COMPARATOR; Interventions: Other: control diet | Arm Label: Pistachio diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Pistachios | Intervention Type: DIETARY_SUPPLEMENT; Name: Pistachios; Assigned to Arm(s): Pistachio diet | Intervention Type: OTHER; Name: control diet; Assigned to Arm(s): Control diet
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Peanuts and peanut butter; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: flaxseed, Behavioral: Health lifestyle counseling | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Behavioral: Health lifestyle counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: flaxseed; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Health lifestyle counseling; Assigned to Arm(s): A, B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects With a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention With Incomplete Revascularization
Brief Summary: This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI; formerly known as angioplasty with stent) on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.


Options:
A: Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): N/A
B: Arm Label: Study Drug Ranexa, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Placebo | Arm Label: Placebo, Then Study Drug Ranexa(Ranolazine); Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Placebo, Then Study Drug Ranexa(Ranolazine), Study Drug Ranexa, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Then Study Drug Ranexa(Ranolazine), Study Drug Ranexa, Then Placebo
C: Arm Label: Ranolazine; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Ranolazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ranolazine placebo | Arm Label: Ranolazine; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Ranolazine placebo | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Ranolazine | Intervention Type: DRUG; Name: Ranolazine placebo; Assigned to Arm(s): Placebo, Ranolazine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LVAD Therapy: Exploring the Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function
Brief Summary: The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe. MPCs are normally present in human bone marrow, and have been shown to increase the development of blood vessels and new heart muscle cells in the heart. In addition, this research is being done to test whether injecting the MPCs into the heart is effective in improving heart function.


Options:
A: Arm Label: MPC Intramyocardial injection; Type: EXPERIMENTAL; Interventions: Biological: MPC Intramyocardial injection | Arm Label: Control Solution; Type: SHAM_COMPARATOR; Interventions: Biological: Control Solution | Intervention Type: BIOLOGICAL; Name: MPC Intramyocardial injection; Assigned to Arm(s): MPC Intramyocardial injection | Intervention Type: BIOLOGICAL; Name: Control Solution; Assigned to Arm(s): Control Solution
B: Intervention Type: GENETIC; Name: Cell Therapy - Autologous CD34 Positive Cells; Assigned to Arm(s): N/A
C: Arm Label: Intramyocardial Injections; Type: EXPERIMENTAL; Interventions: Procedure: Intramyocardial injection | Arm Label: Intracoronary Injections; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intracoronary injection | Arm Label: Ischemic heart disease; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intramyocardial injection | Intervention Type: PROCEDURE; Name: Intramyocardial injection; Assigned to Arm(s): Intramyocardial Injections | Intervention Type: PROCEDURE; Name: Intracoronary injection; Assigned to Arm(s): Intracoronary Injections | Intervention Type: PROCEDURE; Name: Intramyocardial injection; Assigned to Arm(s): Ischemic heart disease
D: Arm Label: Low-dose shock wave treatment & Placebo; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: low-dose shock-wave treatment & Cell therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: High-dose shock-wave treatment & Placebo; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: High-dose shock-wave treatment & cell therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Arm Label: Placebo shock-wave treatment & cell therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intracoronary stem cell therapy | Intervention Type: PROCEDURE; Name: intracoronary stem cell therapy; Assigned to Arm(s): High-dose shock-wave treatment & Placebo, High-dose shock-wave treatment & cell therapy, Low-dose shock wave treatment & Placebo, Placebo shock-wave treatment & cell therapy, low-dose shock-wave treatment & Cell therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth: A CBPR RCT
Brief Summary: The goal of this project is to evaluate the effectiveness of a family-based tobacco use prevention intervention directed at immigrant Latino parents of middle school aged youth as delivered in partnership with seven community organizations. The primary outcomes of the study are youth susceptibility to tobacco use, and changes in parenting practices among the parents of the youth. The planning, initiation, and delivery of the intervention will occur in collaboration with community organizations that have identified this project as important to the families they serve. Though the collaboratively designed training curriculum has been successfully tested and a study design for the current project established, a substantive development period for this project will allow the research team and collaborating organizations to consider key aspects of design and delivery.


Options:
A: Arm Label: 5As Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: 5As Team Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 5As Team Intervention; Assigned to Arm(s): 5As Team Intervention
B: Arm Label: Integrated family-focused PMTCT arm; Type: EXPERIMENTAL; Interventions: Other: Task-shifting to lower-cadre providers at PMTCT sites, Other: POC CD4+ cell count testing, Other: integrated mother-infant care, Other: Prominent role for influential family members (male partners) in collaboration with CHWs | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Task-shifting to lower-cadre providers at PMTCT sites; Assigned to Arm(s): Integrated family-focused PMTCT arm | Intervention Type: OTHER; Name: POC CD4+ cell count testing; Assigned to Arm(s): Integrated family-focused PMTCT arm | Intervention Type: OTHER; Name: integrated mother-infant care; Assigned to Arm(s): Integrated family-focused PMTCT arm | Intervention Type: OTHER; Name: Prominent role for influential family members (male partners) in collaboration with CHWs; Assigned to Arm(s): Integrated family-focused PMTCT arm
C: Arm Label: Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Intervention Type: BEHAVIORAL; Name: Family-Skills Training; Assigned to Arm(s): Control Group, Intervention Group
D: Arm Label: Multifaceted approach; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multifaceted approach | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted approach; Assigned to Arm(s): Multifaceted approach

Answer: C